Global Anti-infective Drugs Market Briefing 2018: Antivirals, Antibiotics, Antifungals, and Others (Antihelmethic, Antiprotozoal) - ResearchAndMarkets.com

DUBLIN--()--The "Anti-infective Drugs Market Global Briefing 2018" report has been added to ResearchAndMarkets.com's offering.

Anti-infective Drugs Market Global Briefing 2018 provides strategists, marketers and senior management with the critical information they need to assess the global anti-infective drugs sector.

Infectious diseases are disorders caused by several pathogenic organisms such as bacteria, viruses, fungi or parasites. These diseases can be transmitted or spread from one person to another through direct contact or indirect contact. Anti-infective drugs are used to treat or prevent these infectious diseases by inhibiting the spread of an infectious agent (static) or by killing the infectious agent (cidal).

North America was the largest region in the anti-infective drugs market in 2017, accounting for around 30% market share. This can be attributed to the presence of established health care networks and high healthcare spending in the region. Asia Pacific was the second largest region accounting for around 21% market share. Western Europe was the third largest region accounting for around 20% market share.

Strategic Collaborations and Agreements - Companies in this market are active with multiple strategic collaborations and agreements. Top companies in the anti-infective drug market are strategically partnering and collaborating with other companies to broaden their products and services.

For instance, in May 2015, Janssen Pharmaceuticals, Inc., subsidiary of Johnson & Johnson has entered into an exclusive worldwide license and collaboration arrangement with Achillion Pharmaceuticals, Inc. to develop and commercialize one or more of Achillion's lead hepatitis C virus (HCV) assets which include ACH-3102, ACH-3422 and sovaprevir.

Also in December 2016, Evotec AG was in a strategic alliance with Forge Therapeutics, Inc. to advance its novel Gram-negative antibiotic programme targeting 'LpxC' for the treatment of bacterial infections. Chimerix and ContraVir Pharmaceuticals also entered into a strategic collaboration for antiviral drug candidate CMX157.

Scope:

  • Markets Covered: Antivirals, Antibiotics, Antifungals, and Others (Antihelmethic, Antiprotozoal).
  • Time Series: Five years historic and forecast.
  • Data: Market value in $ billions.
  • Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

  • Gilead Sciences Inc.
  • Merck & Co.
  • GlaxosmithKline Plc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Pfizer Inc.
  • AbbVie Inc.
  • Novartis AG
  • Bayer AG
  • Otsuka Pharmaceutical Co. Ltd

For more information about this report visit https://www.researchandmarkets.com/research/w7wngq/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs